search
Back to results

Early Gestational Diabetes Mellitus (LEMA_GDM)

Primary Purpose

Gestational Diabetes

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
late management strategy
early management strategy
Sponsored by
University Hospital, Lille
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Gestational Diabetes focused on measuring Early gestational diabetes, pregnancy, fasting plasma glucose, diagnosis, prognosis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Pregnant woman
  • Singleton pregnancy
  • Early GDM defined by a fasting plasma glucose between 5.1 mmol/l and 6.1 mmol/ with at least one risk factor (age ≥35 years and/or BMI ≥ 25 kg/m2 and/or familial history of diabetes and/or personal history of GDM and/or personal history of macrosomia).
  • First prenatal visit prior 20 weeks of gestation at the time of randomization.
  • Signed informed consent

Exclusion Criteria:

Multiple Pregnancy

  • Pre-existing diabetes in pregnancy
  • Renal impairment
  • Hepatic insufficiency
  • History of bariatric surgery
  • Long time corticosteroids treatment
  • Insufficient understanding
  • Language difficulties
  • Lack of social Insurance
  • Refusal to participate in research
  • Person in emergency situation
  • Person under the protection of justice (tutelage/ curatorship)
  • Persons deprived of their liberty

Sites / Locations

  • CH ARRASRecruiting
  • Hopital Estaing - Chu63 - Clermont FerrandRecruiting
  • Hop Claude Huriez Chu LilleRecruiting
  • Hopital Saint Vincent - Saint Antoine - LilleRecruiting
  • Chu Nimes Caremeau - Nimes 9Recruiting
  • Hopital Haut-Leveque - Chu - PessacRecruiting
  • Ch Rene Dubos - PontoiseRecruiting
  • Chu Site Sud (Saint Pierre) - St PierreRecruiting
  • Csapa / Hus / Hopital Civil - StrasbourgRecruiting
  • Hopital de Rangueil Chu ToulouseRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Early management GDM group

Late management GDM group

Arm Description

defined as no intervention until GDM screening at 24-28 weeks' gestation. If there is a diagnosis of GDM at 24-28 according to the IADPSG criteria), intensive metabolic treatment until delivery

early management of GDM defined as intensive metabolic treatment (diet, physical activity self-blood glucose monitoring according and/or insulin therapy according to the French guidelines). This intensive treatment will begin after the randomization until delivery.

Outcomes

Primary Outcome Measures

The occurrence of materno-fetal complications
Composite endpoint defined by Large for Gestational Age (LGA) (defined by birth weight ≥90th percentile, adjusted for gestational age, sex, maternal BMI, parity, ethnicity) and/or neonatal hypoglycemia and/or shoulder dystocia and/or birth traumatisms

Secondary Outcome Measures

Correlation between composite endpoint (defined in the outcome 1) and the 5 risk factors of GDM
Correlation between composite endpoint (defined in the outcome 1) and the 5 risk factors of GDM (age more or equal to 35 years, BMI more or equal to 25 kg/m2, familial history of diabetes, personal history of GDM, personal history of macrosomia)
Need for insulin during pregnancy
After at least 10 days of dietary and lifestyles measures, if the target are not achieved, women will receive insulin therapy. fastin glucose target <5.1 mmol/ and/or a 2 hour post prandial capillary glucose < 6.6 mmol/l at each 10 days a contact with the diabetologist or the nurses for the transmission of the capillary glycaemia either by phone or by the platform 'myDiabby"
Metabolic data: Fasting plasma glucose
Change of value of fasting plasma glucose
Metabolic data: HbA1c
Change of value of HbA1c
Oral Glucose Tolerance Test (OGTT)
Percent of GDM women in the late GDM management group according to the IADPSG criteria.
IADPSG criteria(fasting glucose more or equal to 5.1 mmol/l and/or 1h more or equal to 10.0 mmol/l and /or 2h more or equal to 8.5 mmol/l
Number of complications in each subgroup of the late GDM management group
Maternal and neonatal complication

Full Information

First Posted
June 22, 2020
Last Updated
January 26, 2023
Sponsor
University Hospital, Lille
search

1. Study Identification

Unique Protocol Identification Number
NCT04451915
Brief Title
Early Gestational Diabetes Mellitus
Acronym
LEMA_GDM
Official Title
Late Versus Early Management of Gestational Diabetes Mellitus: a Non Inferiority Randomized Multicenter Trial
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 30, 2020 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Lille

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
In 2010, the International Association of the Diabetes and Pregnancy Study Groups (IADPSG) panel published consensus-based recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Cognizant that milder degrees of hyperglycemia would also be detected by early pregnancy testing, the IADPSG recommended that fasting plasma glucose (FPG) in the range of 5.1-6.9 mmol/l should be considered diagnostic of early Gestational Diabetes Mellitus (GDM) even if the level of proof for this recommendation is very low regarding to prognosis. This threshold was extrapolated from the FPG value used between 24 and 28 weeks. In France, a FPG is proposed at the first prenatal visit for women with risk factors of GDM. Early GDM is diagnosed if FPG is ≥ 5.1 mmol/l, leading to an intensive metabolic management. Data have shown that GDM prevalence increased rapidly from 5.9% in 2009 to 9.3% in 2014. 26.9% of women with hyperglycemia during their pregnancy but without known diabetes are treated before 22 weeks' gestation (WG). More recent data from Italy and China, where IADPSG diagnosis criteria were applied, have strongly challenged this recommendation, and showed that early FPG ≥ 5.1mmo/L is poorly predictive of later GDM. No prior studies have demonstrated benefits to early screening and management. In 2016, the IADPSG members have suggested that the use of the FPG threshold ≥5.1 mmol/l for the identification of GDM in early pregnancy is not justified by current evidence

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gestational Diabetes
Keywords
Early gestational diabetes, pregnancy, fasting plasma glucose, diagnosis, prognosis

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
2010 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Early management GDM group
Arm Type
Experimental
Arm Description
defined as no intervention until GDM screening at 24-28 weeks' gestation. If there is a diagnosis of GDM at 24-28 according to the IADPSG criteria), intensive metabolic treatment until delivery
Arm Title
Late management GDM group
Arm Type
Experimental
Arm Description
early management of GDM defined as intensive metabolic treatment (diet, physical activity self-blood glucose monitoring according and/or insulin therapy according to the French guidelines). This intensive treatment will begin after the randomization until delivery.
Intervention Type
Other
Intervention Name(s)
late management strategy
Intervention Description
late management strategy of GDM defined as no intervention until GDM screening at 24-28 weeks. Between 24-28 weeks gestation, a 75-g OGTT will be done
Intervention Type
Other
Intervention Name(s)
early management strategy
Intervention Description
early management of GDM defined as intensive metabolic treatment. Intensive treatment involved the following multidisciplinary approach: lifestyle defined by diet and exercise intervention according to the French guidelines
Primary Outcome Measure Information:
Title
The occurrence of materno-fetal complications
Description
Composite endpoint defined by Large for Gestational Age (LGA) (defined by birth weight ≥90th percentile, adjusted for gestational age, sex, maternal BMI, parity, ethnicity) and/or neonatal hypoglycemia and/or shoulder dystocia and/or birth traumatisms
Time Frame
at delivery
Secondary Outcome Measure Information:
Title
Correlation between composite endpoint (defined in the outcome 1) and the 5 risk factors of GDM
Description
Correlation between composite endpoint (defined in the outcome 1) and the 5 risk factors of GDM (age more or equal to 35 years, BMI more or equal to 25 kg/m2, familial history of diabetes, personal history of GDM, personal history of macrosomia)
Time Frame
at delivery
Title
Need for insulin during pregnancy
Description
After at least 10 days of dietary and lifestyles measures, if the target are not achieved, women will receive insulin therapy. fastin glucose target <5.1 mmol/ and/or a 2 hour post prandial capillary glucose < 6.6 mmol/l at each 10 days a contact with the diabetologist or the nurses for the transmission of the capillary glycaemia either by phone or by the platform 'myDiabby"
Time Frame
at each 10 days until delivery
Title
Metabolic data: Fasting plasma glucose
Description
Change of value of fasting plasma glucose
Time Frame
at inclusion (because <20 weeks') and an average at 24 28 weeks of gestation
Title
Metabolic data: HbA1c
Description
Change of value of HbA1c
Time Frame
at inclusion (because <20 weeks') and an average at 24 28 weeks of gestation
Title
Oral Glucose Tolerance Test (OGTT)
Time Frame
an average at 24 28 weeks of gestation
Title
Percent of GDM women in the late GDM management group according to the IADPSG criteria.
Description
IADPSG criteria(fasting glucose more or equal to 5.1 mmol/l and/or 1h more or equal to 10.0 mmol/l and /or 2h more or equal to 8.5 mmol/l
Time Frame
an average at 24 28 weeks of gestation
Title
Number of complications in each subgroup of the late GDM management group
Description
Maternal and neonatal complication
Time Frame
at delivery

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
Pregnant women with at least one GDM risk factor and a fasting plasma glucose between 5.1 mmol/l and 6.1 mmol/l prior 20 weeks' gestation.
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Pregnant woman Singleton pregnancy Early GDM defined by a fasting plasma glucose between 5.1 mmol/l and 6.1 mmol/ with at least one risk factor (age ≥35 years and/or BMI ≥ 25 kg/m2 and/or familial history of diabetes and/or personal history of GDM and/or personal history of macrosomia). First prenatal visit prior 20 weeks of gestation at the time of randomization. Signed informed consent Exclusion Criteria: Diabetic follow-up started at time of inclusion Pre-existing diabetes in pregnancy Renal impairment Hepatic insufficiency History of bariatric surgery Long time corticosteroids treatment Insufficient understanding Language difficulties Lack of social Insurance Person in emergency situation Person under the protection of justice (tutelage/ curatorship) Persons deprived of their liberty
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Anne VAMBERGUE, MD,PhD
Phone
0320445962
Email
anne.vambergue@chru-lille.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anne VAMBERGUE
Organizational Affiliation
University Hospital, Lille
Official's Role
Study Director
Facility Information:
Facility Name
CH ARRAS
City
Arras
Country
France
Individual Site Status
Recruiting
Facility Name
Hopital Estaing - Chu63 - Clermont Ferrand
City
Clermont-Ferrand
Country
France
Individual Site Status
Recruiting
Facility Name
Hop Claude Huriez Chu Lille
City
Lille
ZIP/Postal Code
59037
Country
France
Individual Site Status
Recruiting
Facility Contact:
Phone
0320445962
Facility Name
Hopital Saint Vincent - Saint Antoine - Lille
City
Lille
ZIP/Postal Code
59037
Country
France
Individual Site Status
Recruiting
Facility Name
Chu Nimes Caremeau - Nimes 9
City
Nîmes
Country
France
Individual Site Status
Recruiting
Facility Name
Hopital Haut-Leveque - Chu - Pessac
City
Pessac
ZIP/Postal Code
33604
Country
France
Individual Site Status
Recruiting
Facility Name
Ch Rene Dubos - Pontoise
City
Pontoise
Country
France
Individual Site Status
Recruiting
Facility Name
Chu Site Sud (Saint Pierre) - St Pierre
City
Saint-Pierre
Country
France
Individual Site Status
Recruiting
Facility Name
Csapa / Hus / Hopital Civil - Strasbourg
City
Strasbourg
ZIP/Postal Code
67091
Country
France
Individual Site Status
Recruiting
Facility Name
Hopital de Rangueil Chu Toulouse
City
Toulouse
ZIP/Postal Code
31300
Country
France
Individual Site Status
Recruiting

12. IPD Sharing Statement

Learn more about this trial

Early Gestational Diabetes Mellitus

We'll reach out to this number within 24 hrs